Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite index to assess disease activity in ankylosing spondylitis (AS). Criteria for disease activity states and improvement scores are important for use in clinical practice, observational studies, and clinical trials, and have b...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2011-07, Vol.38 (7), p.1502-1506
Main Authors: MACHADO, Pedro M. M. C, LANDEWE, Robert B. M, VAN DER HEIJDE, Desiree M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Disability Evaluation
Diseases of the osteoarticular system
Diseases of the spine
Humans
Inflammatory joint diseases
Medical sciences
Outcome Assessment (Health Care) - methods
Reproducibility of Results
Severity of Illness Index
Spondylitis, Ankylosing - therapy
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new composite index to assess disease activity in ankylosing spondylitis (AS). Criteria for disease activity states and improvement scores are important for use in clinical practice, observational studies, and clinical trials, and have been proposed by the Assessment of SpondyloArthritis international Society (ASAS). At OMERACT 10, our aim was to obtain endorsement from OMERACT for the ASDAS disease activity states and response criteria proposed by the ASAS membership. This article summarizes the associated discussions, the scientific basis of the validation process, and the results from the voting sessions, and identifies areas for research using the ASDAS. OMERACT participants agreed with the selection of cutoff values, which now have the combined endorsement of ASAS and OMERACT and are ready to be used in clinical practice and in research settings.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.110279